Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.